tailieunhanh - báo cáo hóa học: " Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma | Buchegger and Press EJNMMI Research 2011 1 7 http content 1 1 7 9 EJNMMI Research a SpringerOpen Journal LETTER TO THE EDITOR Open Access Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma Franz Buchegger1 2 and Oliver W Press3 4 Abstract Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy RIT consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy. Keywords Radioimmunotherapy consolidation Rituximab maintenance Follicular lymphoma Letter to the Editor The recent review of . Illidge on radioimmunotherapy RIT of lymphoma highlighted the inherent potential of this particular treatment 1 . While convinced of the efficacy of RIT he regretted the low implementation of RIT in current clinical practice. We would like to elaborate further on the biological agents that have shown efficacy in treatment of follicular lymphoma. In a small series of relapsed indolent lymphoma patients treated in Switzerland with 131I-tositu-momab Bexxar GlaxoSmithKline Brentford UK we experienced several long-lasting complete remissions with six of 12 patients 50 reaching 10-years progression free survival without any further treatment 2 . Similar 10-year progression-free survivals after 131I-tosi-tumomab in relapse have been reported by another group though at a somewhat lower rate 3 . The Southwest Oncology Group SWOG has demonstrated that 67 of follicular lymphoma patients remained progression free more than 5 years after consolidation of CHOP chemotherapy with 131I-tositumomab 4 . Yet another group has communicated a 50 complete response CR rate after 10 years following an initial treatment